S&P/ASX 200 Index (ASX: XJO) shares are down 0.2% to 8,815.3 points on Monday.
The market is jittery after Iran said it had re-closed the Strait of Hormuz over the weekend after Israel bombed Lebanon.
US and Iran officials are in Switzerland for further discussions after both parties signed an interim peace deal last week.
Meanwhile on The Bull this week, two experts give us their views and ratings on three ASX 200 shares.
Let's check them out.
Image source: Getty Images
Life360 Inc (ASX: 360)
The Life360 share price is $23.88, up 0.2% today and down 26% in the calendar year to date (YTD).
Christopher Watt from Bell Potter Securities has a buy rating on this ASX 200 tech share.
Watt explains:
This information technology company provides a mobile networking safety app for families.
Active user growth is rebounding following a technical issue, while paying circle growth, which drives revenue, recently exceeded expectations.
Guidance was upgraded. Once focus returns to paying circles, I expect a re-rating to follow.
The upcoming August result is a catalyst.
The company has been enjoying strong price momentum, with the shares rising from $17.91 on May 20 to trade at $22.54 on June 18.
Woodside Energy Group Ltd (ASX: WDS)
The Woodside share price is $29.18, up 0.5% today and up 23% YTD.
Niv Dagan from Peak Asset Management has a hold rating on this ASX 200 energy share.
Dagan said:
Operationally, the energy giant continues to execute strongly. It achieved an 11 per cent increase in the average realised price of a barrel of oil equivalent in the first quarter of 2026 when compared to the fourth quarter of financial year 2025.
However, quarterly production fell by 8 per cent due to seasonal weather events. The Scarborough energy project was 96 per cent complete and remains on track for first LNG cargo in the fourth quarter of 2026.
Other major projects remain on budget and on schedule.
CSL Ltd (ASX: CSL)
CSL shares are $113.09, down 2.8% today and down 34% YTD.
Dagan has a sell rating on this ASX 200 healthcare share.
The analyst said CSL shares deserve a sell rating after the company downgraded its outlook for FY26.
He commented:
A sell rating is justified as this biotechnology giant has materially downgraded its fiscal year 2026 outlook while announcing about $5 billion of additional non-cash pre-tax impairments across fiscal years 2026 and 2027.
Revenue expectations have been reduced due to US immunoglobulin channel normalisation and weaker albumin prices in China.
The CSL Vifor acquisition has under-performed. Also, government healthcare cost pressures and a higher interest rate environment present ongoing challenges for the biotechnology sector, further weighing on sentiment.
